Showing results (201-210 of 233) with videos related to

Sort By:
Pageof 24
ESMO Open|April 23, 2024
Immune checkpoint blockers in solid organ transplant recipients and cancer: the INNOVATED cohortJ Remon, E Auclin, L Zubiri, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 16, 2026
MTAP Loss Is Frequent in Oncogene-Driven NSCLC and May Confer Sensitivity to Combined PRMT5 Inhibitors and Targeted TherapiesM Aldea, S Lenahan, M-A Locquet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 25, 2015
Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohortJ Mazières, F Barlesi, T Filleron, et al.
Diagnostic and Interventional Imaging|October 6, 2020
Radiofrequency ablation versus surgical resection for the treatment of oligometastatic lung diseaseL Tselikas, L Garzelli, O Mercier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 28, 2015
A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†G R Blumenschein, E F Smit, D Planchard, et al.
British Journal of Cancer|February 18, 2010
Prevalence, risk factors and clinical implications of malnutrition in French Comprehensive Cancer CentresM Pressoir, S Desné, D Berchery, et al.
Bulletin Du Cancer|November 12, 2009
[Setting up supportive care in oncology: reflexions and suggestions.]P Colombat, S Antoun, R Aubry, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 10, 2015
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trialM Schuler, J C-H Yang, K Park, et al.
ESMO Open|November 18, 2025
Immunotherapy beyond progression combined with platinum-based chemotherapy after primary resistance to first-line immunotherapy in patients with advanced NSCLC and PD-L1 ≥50A De Giglio, L Zullo, A Di Federico, et al.
Molecular Cancer|November 13, 2024
The PI3K-AKT-mTOR axis persists as a therapeutic dependency in KRAS<sup>G12D</sup>-driven non-small cell lung cancerW J McDaid, L Wilson, H Adderley, et al.
Pageof 24